DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes
EA Griffiths, SD Gore - Seminars in hematology, 2008 - Elsevier
The recently approved drugs 5-azacitidine (5AC) and 5-aza-2′-deoxyazacytidine (DAC)
are in wide clinical use for the treatment of myelodysplastic syndrome (MDS) of all types and
chronic myelomonocytic leukemia (CMML). These agents were developed based upon an
understanding of the importance of epigenetic changes in malignancy, and they have been
evaluated in randomized clinical trials, which demonstrate response rates between 20% and
40% in patients for whom no previous standard of care was available. As understanding of …
are in wide clinical use for the treatment of myelodysplastic syndrome (MDS) of all types and
chronic myelomonocytic leukemia (CMML). These agents were developed based upon an
understanding of the importance of epigenetic changes in malignancy, and they have been
evaluated in randomized clinical trials, which demonstrate response rates between 20% and
40% in patients for whom no previous standard of care was available. As understanding of …